Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and Evergreen Theragnostics, a radiopharmaceutical contract manufacturer, have entered into an agreement whereby Evergreen will provide U.S.-based manufacturing for Precirix’s lead product candidate, CAM-H2.
 
CAM-H2 is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer. The novel precision therapy aims to effectively irradiate cancer lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable characteristics of single-domain antibodies.
 
“Establishing a strong manufacturing footprint in North America is an important step for Precirix to ensure reliable clinical trial supply,” said Ruth Devenyns, CEO, Precirix. “We are very pleased to be working with Evergreen, a team with solid expertise and a proven track record in radiopharmaceutical manufacturing.”
 
Evergreen will manufacture CAM-H2, an I-131 based radiopharmaceutical, at its new state-of-the-art facility in Springfield, NJ. Opening in 2021, the facility is located near Newark Liberty International Airport and within driving distance of John F. Kennedy International Airport. The location is ideal for receiving isotope shipments from Europe and distributing finished product to hospitals across North America.
 
“CAM-H2 is a very promising product with potential to significantly improve outcomes for patients with HER2-positive cancer,” said James Cook, CEO, Evergreen. “We are pleased to be working together with an outstanding team at Precirix. Evergreen is committed to ensuring reliable supply throughout these important clinical studies.”